Albert Seymour
Directeur Général chez Seamless Therapeutics
Fortune : 236 708 $ au 30/04/2024
Profil
Albert Seymour is currently the President & Chief Executive Officer at Seamless Therapeutics and a Director at Ensoma, Inc. Previously, he served as the President, Chief Executive Officer & Director at Homology Medicines, Inc. from 2016 to 2023 and as the Senior VP, Head-Global Research & Nonclinical at Shire Pharmaceuticals, Inc. from 2011 to 2016.
Dr. Seymour holds a doctorate degree from the University of Pittsburgh, a graduate degree from The Johns Hopkins University, and an undergraduate degree from the University of Delaware.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
0,07% | 06/09/2023 | 8 382 ( 0,07% ) | 236 708 $ | 30/04/2024 |
Postes actifs de Albert Seymour
| Sociétés | Poste | Début |
|---|---|---|
Ensoma, Inc.
 Ensoma, Inc. Miscellaneous Commercial ServicesCommercial Services Ensoma, Inc. believes in the future of medicine and is committed to creating a new therapeutic category to tackle diseases that affect millions around the world, such as cancer and autoimmune disease, as well as inherited conditions. Ensoma is based in Boston, MA and has subsidiaries in Denmark. The company's engenious™ platform combines innovative delivery technology with the full DNA editing toolkit to address these disorders. Ensoma is supported by top-tier investors, a strategic collaboration with Takeda, and a passionate team. The company was founded by André Lieber, Hans-Peter Kiem, Kush M. Parmar, and the CEO is Emile F. Nuwaysir. | Directeur/Membre du Conseil | - |
Seamless Therapeutics
 Seamless Therapeutics Packaged SoftwareTechnology Services Seamless Therapeutics is a German company that is changing the paradigm of gene editing by unlocking the full potential of recombinases. The company is based in Dresden, Germany. The company is developing a pipeline of disease-modifying product candidates across a broad spectrum of indications to expand the therapeutic potential of gene editing. | Directeur Général | 23/04/2024 |
Anciens postes connus de Albert Seymour
| Sociétés | Poste | Fin |
|---|---|---|
| Q32 BIO INC. | Directeur Général | 17/11/2023 |
Shire Pharmaceuticals, Inc.
 Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA | Corporate Officer/Principal | 01/03/2016 |
Formation de Albert Seymour
| University of Delaware | Undergraduate Degree |
| The Johns Hopkins University | Graduate Degree |
| University of Pittsburgh | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Homology Medicines, Inc.
 Homology Medicines, Inc. Pharmaceuticals: MajorHealth Technology Homology Medicines, Inc. is a clinical-stage genetic medicines company, which engages in the translation of proprietary gene editing and gene therapy technology into novel treatments for patients with rare genetic diseases. The company was founded in March 2015 and is headquartered in Bedford, MA. | Health Technology |
Shire Pharmaceuticals, Inc.
Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA | Health Technology |
Ensoma, Inc.
Ensoma, Inc. Miscellaneous Commercial ServicesCommercial Services Ensoma, Inc. believes in the future of medicine and is committed to creating a new therapeutic category to tackle diseases that affect millions around the world, such as cancer and autoimmune disease, as well as inherited conditions. Ensoma is based in Boston, MA and has subsidiaries in Denmark. The company's engenious™ platform combines innovative delivery technology with the full DNA editing toolkit to address these disorders. Ensoma is supported by top-tier investors, a strategic collaboration with Takeda, and a passionate team. The company was founded by André Lieber, Hans-Peter Kiem, Kush M. Parmar, and the CEO is Emile F. Nuwaysir. | Commercial Services |
Seamless Therapeutics
Seamless Therapeutics Packaged SoftwareTechnology Services Seamless Therapeutics is a German company that is changing the paradigm of gene editing by unlocking the full potential of recombinases. The company is based in Dresden, Germany. The company is developing a pipeline of disease-modifying product candidates across a broad spectrum of indications to expand the therapeutic potential of gene editing. | Technology Services |